Directorio

This study lasts for about 41 weeks. It starts with a screening period, followed by around 6 months of taking either the study medicine or a placebo, and ends with a follow-up visit. People who join will be randomly chosen to get either a low dose or high dose of the medicine called PKN605, or a placebo, which is a pill that does not have any medicine in it. During the study, participants will go to the clinic regularly. They will wear a heart monitor patch, use a small device at home to check their heart, and have blood tests and other health checks. These tests help doctors learn how the medicine works and if it is safe.

This study has two groups, and you will have an equal chance of being in either one. In Group 1, people get the usual treatment for advanced prostate cancer. This includes hormonal therapy, which can be given as a shot or as pills, and apalutamide, which is taken as four pills once a day. In Group 2, people get a chemotherapy drug called docetaxel along with the usual hormonal therapy and apalutamide. Docetaxel is given through a vein every three weeks for up to six doses. People in this group also get steroids through an IV on the day they receive docetaxel to help reduce side effects.

We are doing this study to compare two different treatment options for mantle cell lymphoma. We want to find out which option has the best outcomes for older adults. We will compare the results of continuous treatment with zanubritinib to treatment with zanubrutinib that is stopped after the initial six 28-day cycles of chemotherapy and restarted only if your disease gets worse following the initial six 28-day cycles of chemotherapy.

We are doing this study to see if combining immunotherapy with chemotherapy is a better treatment than chemotherapy alone for NSCLC.

We are doing this study to help create a national biobank of samples and data about patients who experience side effects when they take immunotherapy drugs for their cancer. We want to find out why some people experience side effects and why others do not. We also want to learn more about how to diagnose and treat these side effects more effectively.

We are doing this study to test a new strategy to help people quit smoking. We want to know if the study approach is better than the usual approach. The usual approach is to encourage patients to quit smoking using cessation support manuals and either medication or nicotine replacement products. We want to know if the study approach works better for cancer survivors who live in rural areas.

We are doing this study to find out if an experimental gene therapy drug called ABBV-RGX-314 (the study drug) has similar effects to approved drugs, such as Lucentis® or Eylea® injections. The study drug will be injected into one eye with a Suprachoroidal Space (SCS) Microinjector®, which is an investigational needle device developed by Clearside Biomedical, Inc.